NOTRELOAD AI
  • NOTRELOAD AI
  • Stocks BUZZ.
  • #TrumpTrade
  • 24-HOUR Pass →
  • Invest ↗
Sign in Subscribe

Major Upgrade for Citius Oncology: Lymphir Launch Anticipation

Citius upgraded to Buy ($6). Lymphir launches in Q4 at high prices ($300K). Sales should jump fast starting in 2026.

Major Upgrade for Citius Oncology: Lymphir Launch Anticipation
Credit: Citius Oncology
Already have an account? Sign in.
09/23/2025 · 8:42 AM
CTOR
/ Read more

Feed↓

FDA Rejects Regenxbio's Gene Therapy for Hunter Syndrome After Clinical Hold
02/09/2026 · 4:34 PM

FDA Rejects Regenxbio's Gene Therapy for Hunter Syndrome After Clinical Hold

FDA issues Complete Response Letter rejecting RGX-121 gene therapy for Hunter syndrome, citing trial design concerns. Regenxbio plans to resubmit with additional data.

/ Subscriber only
Roblox Stock Upgraded to Buy as Growth Outlook Strengthens
02/09/2026 · 3:35 PM

Roblox Stock Upgraded to Buy as Growth Outlook Strengthens

Roth Capital upgrades Roblox to Buy with an $84 price target, citing strong bookings growth, improved game quality, and rising older player engagement.

/ Subscriber only
Trump Endorses Nexstar-Tegna $6.2B Merger After Reversal
02/09/2026 · 12:32 PM

Trump Endorses Nexstar-Tegna $6.2B Merger After Reversal

President Trump endorses Nexstar's $6.2B Tegna acquisition, reversing earlier criticism. Deal would create largest local TV operator covering 80% of U.S. households.

/ Subscriber only
  • UP↑
  • Terms/Privacy
  • Sign up
  • Sign in
  • Discord
  • X
  • Bluesky
  • Telegram
  • Reach out →
  • Invest ↗
  • NOTRELOAD AI
DON'T FALL BEHIND. ©2025
Email address Subscribe